201 related articles for article (PubMed ID: 36199064)
1. Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.
Xie D; Li Y; Xu M; Zhao X; Chen M
Cardiovasc Diabetol; 2022 Oct; 21(1):200. PubMed ID: 36199064
[TBL] [Abstract][Full Text] [Related]
2. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus.
Yue WS; Lau KK; Siu CW; Wang M; Yan GH; Yiu KH; Tse HF
Cardiovasc Diabetol; 2011 Dec; 10():113. PubMed ID: 22185563
[TBL] [Abstract][Full Text] [Related]
3. Dulaglutide restores endothelial progenitor cell levels in diabetic mice and mitigates high glucose-induced endothelial injury through SIRT1-mediated mitochondrial fission.
Mei X; Li Y; Wu J; Liao L; Lu D; Qiu P; Yang HL; Tang MW; Liang XY; Liu D
Biochem Biophys Res Commun; 2024 Jul; 716():150002. PubMed ID: 38697011
[TBL] [Abstract][Full Text] [Related]
4. Expression of miR-210 in the peripheral blood of patients with newly diagnosed type 2 diabetes mellitus and its effect on the number and function of endothelial progenitor cells.
Li X; Jia Z; Zhao X; Xu M; Chen M
Microvasc Res; 2020 Sep; 131():104032. PubMed ID: 32533960
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.
Wang J; Li HQ; Xu XH; Kong XC; Sun R; Jing T; Ye L; Su XF; Ma JH
Biomed Res Int; 2019; 2019():2682657. PubMed ID: 31950036
[No Abstract] [Full Text] [Related]
6. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
[TBL] [Abstract][Full Text] [Related]
11. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
Frias JP; Wynne AG; Matyjaszek-Matuszek B; Bartaskova D; Cox DA; Woodward B; Li YG; Tham LS; Milicevic Z
Diabetes Obes Metab; 2019 Sep; 21(9):2048-2057. PubMed ID: 31050143
[TBL] [Abstract][Full Text] [Related]
14. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
Umpierrez G; Tofé Povedano S; Pérez Manghi F; Shurzinske L; Pechtner V
Diabetes Care; 2014 Aug; 37(8):2168-76. PubMed ID: 24842985
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes.
Longo M; Di Meo I; Caruso P; Muscio MF; Scappaticcio L; Maio A; Maiorino MI; Bellastella G; Signoriello G; Knop FK; Rizzo MR; Esposito K
Diabetes Res Clin Pract; 2023 Jun; 200():110688. PubMed ID: 37116797
[TBL] [Abstract][Full Text] [Related]
17. Hyperglycemia and Advanced Glycation End Products Regulate miR-126 Expression in Endothelial Progenitor Cells.
Li Y; Zhou Q; Pei C; Liu B; Li M; Fang L; Sun Y; Li Y; Meng S
J Vasc Res; 2016; 53(1-2):94-104. PubMed ID: 27673690
[TBL] [Abstract][Full Text] [Related]
18. Dulaglutide: A Review in Type 2 Diabetes.
Burness CB; Scott LJ
BioDrugs; 2015 Dec; 29(6):407-18. PubMed ID: 26423061
[TBL] [Abstract][Full Text] [Related]
19. Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
Arslanian SA; Hannon T; Zeitler P; Chao LC; Boucher-Berry C; Barrientos-Pérez M; Bismuth E; Dib S; Cho JI; Cox D;
N Engl J Med; 2022 Aug; 387(5):433-443. PubMed ID: 35658022
[TBL] [Abstract][Full Text] [Related]
20. Interaction of platelets with endothelial progenitor cells in the experimental atherosclerosis: Role of transplanted endothelial progenitor cells and platelet microparticles.
Alexandru N; Andrei E; Dragan E; Georgescu A
Biol Cell; 2015 Jun; 107(6):189-204. PubMed ID: 25763472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
